Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-SARS-CoV-2 receptor binding domain antibodies after the second dose of Sinovac and AstraZeneca vaccination

  • Marisca Evalina Gondokesumo (Faculty of Pharmacy, University of Surabaya) ;
  • Anita Purnamayanti (Faculty of Pharmacy, University of Surabaya) ;
  • Puri Safitri Hanum (Faculty of Medicine, University of Surabaya) ;
  • Winnie Nirmala Santosa (Faculty of Medicine, University of Surabaya) ;
  • Ardyan Prima Wardhana (Faculty of Medicine, University of Surabaya) ;
  • Christina Avanti (Faculty of Pharmacy, University of Surabaya)
  • Received : 2023.01.04
  • Accepted : 2023.07.21
  • Published : 2023.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The Sinovac and AstraZeneca vaccines are the primary coronavirus disease 2019 vaccines in Indonesia. Antibody levels in vaccine-injected individuals will decline substantially over time, but data supporting the duration of such responses are limited. Therefore, this study aims to quantitatively evaluate antibody responses resulting from the completion of Sinovac and AstraZeneca administration in Indonesian adults. Materials and Methods: Participants were divided into two groups based on their vaccine type. Both groups were then assessed on the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (anti-SRBD) concentrations. The anti-SRBD level was measured using Elecsys anti-SARS-CoV-2 S assay and analyzed every month until 3 months after the second vaccination. Results: The results presented significant differences (p=0.000) in immunoglobulin G (IgG) titers among the vaccines' measurement duration, where all samples observed a decrease in IgG titers over time. The mean titer levels of anti-SRBD IgG in the group given Sinovac were high in the first month after vaccination and decreased by 55.7% in 3 months. AstraZeneca showed lesser immune response with a slower decline rate. Adverse effects following immunization (AEFI) showed that systemic reactions are the most reported in both vaccines, with a higher percentage in the second dose of AstraZeneca type vaccines. Conclusion: Sinovac induced more significant titers of anti-SRBD IgG 1 month after the second dose but generated fewer AEFIs. In contrast, AstraZeneca generated more AEFIs, in mild to moderate severity, but provided lower levels of anti-SRBD IgG.

Keywords

References

  1. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020;11:585354. 
  2. Santi T, Sungono V, Kamarga L, et al. Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clin Exp Vaccine Res 2022;11:209-16. 
  3. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-92. 
  4. Palacios R, Patino EG, de Oliveira Piorelli R, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac-PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials 2020;21:853. 
  5. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021;39:4423-8. 
  6. Fu D, Zhang G, Wang Y, et al. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. PLoS Biol 2021;19:e3001209. 
  7. Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020;588:682-7. 
  8. World Health Organization. Coronavirus (COVID-19) dashboard [Internet]. Geneva: World Health Organization; 2022 [cited 2022 Sep 9]. Available from: https://covid19.who.int 
  9. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol 2021;59:e03149-20. 
  10. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032-40. 
  11. Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT. SARS-CoV-2 vaccines in advanced clinical trials: where do we stand? Adv Drug Deliv Rev 2021;172:314-38. 
  12. Santi T, Samakto B, Kamarga L, Hidayat FK, Hidayat F. Factors associated with SARS-CoV-2 antibody titer after sinovac vaccination among health care workers. Acta Med Indones 2021;53:374-84. 
  13. Angkasekwinai N, Sewatanon J, Niyomnaitham S, et al. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. Vaccine X 2022;10:100153. 
  14. Foddis R, Marino R, Silvestri R, et al. Evaluation of the anti-spike (RDB) IgG titer among workers employed at the university of pisa vaccinated with different types of SARS-CoV-2 vaccines. Vaccines (Basel) 2022;10:1244. 
  15. Salvagno GL, Henry BM, di Piazza G, et al. Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination. Diagnostics (Basel) 2021;11:832. 
  16. Lo Sasso B, Giglio RV, Vidali M, et al. Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine. Diagnostics (Basel) 2021;11:1135. 
  17. Favresse J, Bayart JL, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect 2021;10:1495-8. 
  18. Barin B, Kasap U, Selcuk F, Volkan E, Uluckan O. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe 2022;3:e274-83. 
  19. Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. Hum Vaccin Immunother 2022;18:2029111. 
  20. Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 2015;14:309-21. 
  21. Wagner A, Garner-Spitzer E, Jasinska J, et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 2018;8:9825. 
  22. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396:1979-93. 
  23. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 2021;27:270-8. 
  24. Lee SW, Moon JY, Lee SK, et al. Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: lack of association with age, sex, obesity, and adverse reactions. Front Immunol 2021;12:779212. 
  25. Pellini R, Venuti A, Pimpinelli F, et al. Early onset of SARS-COV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI. Vaccines (Basel) 2021;9:685. 
  26. Islam Z, Yamamoto S, Mizoue T, et al. Association of impaired fasting glucose and diabetes with SARS-CoV-2 spike antibody titers after the BNT162b2 vaccine among health care workers in a tertiary hospital in Japan. Vaccines (Basel) 2022;10:776. 
  27. D'Addio F, Sabiu G, Usuelli V, et al. Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes. Diabetes 2022;71:1800-6. 
  28. Shomali N, Mahmoudi J, Mahmoodpoor A, et al. Harmful effects of high amounts of glucose on the immune system: an updated review. Biotechnol Appl Biochem 2021;68:404-10. 
  29. Mayasari NR, Ho DK, Lundy DJ, et al. Impacts of the COVID-19 pandemic on food security and diet-related lifestyle behaviors: an analytical study of Google Trends-based query volumes. Nutrients 2020;12:3103. 
  30. Ozgocer T, Dagli SN, Ceylan MR, Disli F, Ucar C, Yildiz S. Analysis of long-term antibody response in COVID-19 patients by symptoms grade, gender, age, BMI, and medication. J Med Virol 2022;94:1412-8. 
  31. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 2020;12:988. 
  32. Murdaca G, Tonacci A, Negrini S, et al. Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications. Autoimmun Rev 2019;18:102350. 
  33. Di Matteo G, Spano M, Grosso M, et al. Food and COVID-19: preventive/co-therapeutic strategies explored by current clinical trials and in silico studies. Foods 2020;9:1036. 
  34. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur 2021;10:100208. 
  35. Zhuang CL, Lin ZJ, Bi ZF, et al. Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. Emerg Microbes Infect 2021;10:365-75. 
  36. Park JW, Lagniton PN, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 2021;17:1446-60.